|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cheng TY, Cramb SM, Baade PD, Youlden DR,
Nwogu C and Reid ME: The international epidemiology of lung cancer:
Latest trends, disparities, and tumor characteristics. J Thorac
Oncol. 11:1653–1671. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Forde PM and Ettinger DS: Targeted therapy
for non-small-cell lung cancer: Past, present and future. Expert
Rev Anticancer Ther. 13:745–758. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Novello S, Barlesi F, Califano R, Cufer T,
Ekman S, Levra MG, Kerr K, Popat S, Reck M, Senan S, et al: ESMO
Guidelines Committee: Metastatic non-small-cell lung cancer: ESMO
Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 27 Suppl 5:v1–v27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim ES: Chemotherapy Resistance in Lung
Cancer. Adv Exp Med Biol. 893:189–209. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rahman I, Biswas SK and Kode A: Oxidant
and antioxidant balance in the airways and airway diseases. Eur J
Pharmacol. 533:222–239. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang JY, Wang Y and Prakash C:
Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab.
7:939–948. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jaramillo MC and Zhang DD: The emerging
role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev.
27:2179–2191. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma Q: Role of nrf2 in oxidative stress and
toxicity. Annu Rev Pharmacol Toxicol. 53:401–426. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Singh A, Misra V, Thimmulappa RK, Lee H,
Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E,
et al: Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung
cancer. PLoS Med. 3:e4202006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ohta T, Iijima K, Miyamoto M, Nakahara I,
Tanaka H, Ohtsuji M, Suzuki T, Kobayashi A, Yokota J, Sakiyama T,
et al: Loss of Keap1 function activates Nrf2 and provides
advantages for lung cancer cell growth. Cancer Res. 68:1303–1309.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang R, An J, Ji F, Jiao H, Sun H and Zhou
D: Hypermethylation of the Keap1 gene in human lung cancer cell
lines and lung cancer tissues. Biochem Biophys Res Commun.
373:151–154. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vollrath V, Wielandt AM, Iruretagoyena M
and Chianale J: Role of Nrf2 in the regulation of the Mrp2 (ABCC2)
gene. Biochem J. 395:599–609. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lu MC, Ji JA, Jiang ZY and You QD: The
Keap1-Nrf2-ARE pathway as a potential preventive and therapeutic
target: An update. Med Res Rev. 36:924–963. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sporn MB and Liby KT: NRF2 and cancer: The
good, the bad and the importance of context. Nat Rev Cancer.
12:564–571. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Villeneuve NF, Lau A and Zhang DD:
Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin
proteasome system: An insight into cullin-ring ubiquitin ligases.
Antioxid Redox Signal. 13:1699–1712. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Menegon S, Columbano A and Giordano S: The
dual roles of NRF2 in cancer. Trends Mol Med. 22:578–593. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kobayashi A, Kang MI, Okawa H, Ohtsuji M,
Zenke Y, Chiba T, Igarashi K and Yamamoto M: Oxidative stress
sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to
regulate proteasomal degradation of Nrf2. Mol Cell Biol.
24:7130–7139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Theodore M, Kawai Y, Yang J, Kleshchenko
Y, Reddy SP, Villalta F and Arinze IJ: Multiple nuclear
localization signals function in the nuclear import of the
transcription factor Nrf2. J Biol Chem. 283:8984–8994. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Padmanabhan B, Tong KI, Ohta T, Nakamura
Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S and
Yamamoto M: Structural basis for defects of Keap1 activity provoked
by its point mutations in lung cancer. Mol Cell. 21:689–700. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim YR, Oh JE, Kim MS, Kang MR, Park SW,
Han JY, Eom HS, Yoo NJ and Lee SH: Oncogenic NRF2 mutations in
squamous cell carcinomas of oesophagus and skin. J Pathol.
220:446–451. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nioi P and Nguyen T: A mutation of Keap1
found in breast cancer impairs its ability to repress Nrf2
activity. Biochem Biophys Res Commun. 362:816–821. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Taguchi K and Yamamoto M: The KEAP1-NRF2
system in cancer. Front Oncol. 7:852017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Muscarella LA, Parrella P, D'Alessandro V,
la Torre A, Barbano R, Fontana A, Tancredi A, Guarnieri V, Balsamo
T, Coco M, et al: Frequent epigenetics inactivation of KEAP1 gene
in non-small cell lung cancer. Epigenetics. 6:710–719. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khor TO, Fuentes F, Shu L,
Paredes-Gonzalez X, Yang AY, Liu Y, Smiraglia DJ, Yegnasubramanian
S, Nelson WG and Kong AN: Epigenetic DNA methylation of
antioxidative stress regulator NRF2 in human prostate cancer.
Cancer Prev Res (Phila). 7:1186–1197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo Y, Yu S, Zhang C and Kong AN:
Epigenetic regulation of Keap1-Nrf2 signaling. Free Radic Biol Med.
88:337–349. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen W, Sun Z, Wang XJ, Jiang T, Huang Z,
Fang D and Zhang DD: Direct interaction between Nrf2 and
p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response.
Mol Cell. 34:663–673. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Williams AB and Schumacher B: p53 in the
DNA-damage-repair process. Cold Spring Harb Perspect Med.
6:a0260702016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Komatsu M, Kurokawa H, Waguri S, Taguchi
K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, et
al: The selective autophagy substrate p62 activates the stress
responsive transcription factor Nrf2 through inactivation of Keap1.
Nat Cell Biol. 12:213–223. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Faraonio R, Vergara P, Di Marzo D,
Pierantoni MG, Napolitano M, Russo T and Cimino F: p53 suppresses
the Nrf2-dependent transcription of antioxidant response genes. J
Biol Chem. 281:39776–39784. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ichimura Y, Waguri S, Sou YS, Kageyama S,
Hasegawa J, Ishimura R, Saito T, Yang Y, Kouno T, Fukutomi T, et
al: Phosphorylation of p62 activates the Keap1-Nrf2 pathway during
selective autophagy. Mol Cell. 51:618–631. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Taguchi K, Fujikawa N, Komatsu M, Ishii T,
Unno M, Akaike T, Motohashi H and Yamamoto M: Keap1 degradation by
autophagy for the maintenance of redox homeostasis. Proc Natl Acad
Sci USA. 109:13561–13566. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
DeNicola GM, Karreth FA, Humpton TJ,
Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES,
et al: Oncogene-induced Nrf2 transcription promotes ROS
detoxification and tumorigenesis. Nature. 475:106–109. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kinch L, Grishin NV and Brugarolas J:
Succination of Keap1 and activation of Nrf2-dependent antioxidant
pathways in FH-deficient papillary renal cell carcinoma type 2.
Cancer Cell. 20:418–420. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Adam J, Hatipoglu E, O'Flaherty L,
Ternette N, Sahgal N, Lockstone H, Baban D, Nye E, Stamp GW,
Wolhuter K, et al: Renal cyst formation in Fh1-deficient mice is
independent of the Hif/Phd pathway: Roles for fumarate in KEAP1
succination and Nrf2 signaling. Cancer Cell. 20:524–537. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
DeNicola GM, Chen PH, Mullarky E, Sudderth
JA, Hu Z, Wu D, Tang H, Xie Y, Asara JM, Huffman KE, et al: NRF2
regulates serine biosynthesis in non-small cell lung cancer. Nat
Genet. 47:1475–1481. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mitsuishi Y, Taguchi K, Kawatani Y,
Shibata T, Nukiwa T, Aburatani H, Yamamoto M and Motohashi H: Nrf2
redirects glucose and glutamine into anabolic pathways in metabolic
reprogramming. Cancer Cell. 22:66–79. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Goldstein LD, Lee J, Gnad F, Klijn C,
Schaub A, Reeder J, Daemen A, Bakalarski CE, Holcomb T, Shames DS,
et al: Recurrent loss of NFE2L2 Exon 2 is a mechanism for Nrf2
pathway activation in human cancers. Cell Rep. 16:2605–2617. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shibata T, Ohta T, Tong KI, Kokubu A,
Odogawa R, Tsuta K, Asamura H, Yamamoto M and Hirohashi S: Cancer
related mutations in NRF2 impair its recognition by Keap1-Cul3 E3
ligase and promote malignancy. Proc Natl Acad Sci USA.
105:13568–13573. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chowdhry S, Zhang Y, McMahon M, Sutherland
C, Cuadrado A and Hayes JD: Nrf2 is controlled by two distinct
β-TrCP recognition motifs in its Neh6 domain, one of which can be
modulated by GSK-3 activity. Oncogene. 32:3765–3781. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Koundouros N and Poulogiannis G:
Phosphoinositide 3-kinase/Akt signaling and redox metabolism in
cancer. Front Oncol. 8:1602018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Inoue D, Suzuki T, Mitsuishi Y, Miki Y,
Suzuki S, Sugawara S, Watanabe M, Sakurada A, Endo C, Uruno A, et
al: Accumulation of p62/SQSTM1 is associated with poor prognosis in
patients with lung adenocarcinoma. Cancer Sci. 103:760–766. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yang H, Wang W, Zhang Y, Zhao J, Lin E,
Gao J and He J: The role of NF-E2-related factor 2 in predicting
chemoresistance and prognosis in advanced non-small-cell lung
cancer. Clin Lung Cancer. 12:166–171. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Solis LM, Behrens C, Dong W, Suraokar M,
Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN,
et al: Nrf2 and Keap1 abnormalities in non-small cell lung
carcinoma and association with clinicopathologic features. Clin
Cancer Res. 16:3743–3753. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li QK, Singh A, Biswal S, Askin F and
Gabrielson E: KEAP1 gene mutations and NRF2 activation are common
in pulmonary papillary adenocarcinoma. J Hum Genet. 56:230–234.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kim Y, Hammerman PS, Kim J, Yoon JA, Lee
Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, et al:
Integrative and comparative genomic analysis of lung squamous cell
carcinomas in East Asian patients. J Clin Oncol. 32:121–128. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Frank R, Scheffler M, Merkelbach-Bruse S,
Ihle MA, Kron A, Rauer M, Ueckeroth F, König K, Michels S, Fischer
R, et al: Clinical and pathological characteristics of KEAP1- and
NFE2L2-mutated non-small cell lung carcinoma (NSCLC). Clin Cancer
Res. 24:3087–3096. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Campbell JD, Alexandrov A, Kim J, Wala J,
Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, et
al: Cancer Genome Atlas Research Network: Distinct patterns of
somatic genome alterations in lung adenocarcinomas and squamous
cell carcinomas. Nat Genet. 48:607–616. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hayes JD and McMahon M: NRF2 and KEAP1
mutations: Permanent activation of an adaptive response in cancer.
Trends Biochem Sci. 34:176–188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Cancer Genome Atlas Research Network:
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Riely GJ, Jordan E, Kim HR, Yu HA, Berger
MF and Solit DB: Association of outcomes and co-occurring genomic
alterations in patients with KRAS-mutant non-small cell lung
cancer. J Clin Oncol. 34:90192016. View Article : Google Scholar
|
|
52
|
Rizvi NA, Hellmann MD, Snyder A, Kvistborg
P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer
immunology. Mutational landscape determines sensitivity to PD-1
blockade in non-small cell lung cancer. Science. 348:124–128. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Scheel AH, Ansén S, Schultheis AM,
Scheffler M, Fischer RN, Michels S, Hellmich M, George J, Zander T,
Brockmann M, et al: PD-L1 expression in non-small cell lung cancer:
Correlations with genetic alterations. Oncoimmunology.
5:e11313792016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bethune G, Bethune D, Ridgway N and Xu Z:
Epidermal growth factor receptor (EGFR) in lung cancer: An overview
and update. J Thorac Dis. 2:48–51. 2010.PubMed/NCBI
|
|
55
|
Seshacharyulu P, Ponnusamy MP, Haridas D,
Jain M, Ganti AK and Batra SK: Targeting the EGFR signaling pathway
in cancer therapy. Expert Opin Ther Targets. 16:15–31. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Papaiahgari S, Yerrapureddy A, Hassoun PM,
Garcia JG, Birukov KG and Reddy SP: EGFR-activated signaling and
actin remodeling regulate cyclic stretch-induced NRF2-ARE
activation. Am J Respir Cell Mol Biol. 36:304–312. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Jacobsen K, Bertran-Alamillo J, Molina MA,
Teixidó C, Karachaliou N, Pedersen MH, Castellví J, Garzón M,
Codony-Servat C, Codony-Servat J, et al: Convergent Akt activation
drives acquired EGFR inhibitor resistance in lung cancer. Nat
Commun. 8:4102017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Huo L, Li CW, Huang TH, Lam YC, Xia W, Tu
C, Chang WC, Hsu JL, Lee DF, Nie L, et al: Activation of Keap1/Nrf2
signaling pathway by nuclear epidermal growth factor receptor in
cancer cells. Am J Transl Res. 6:649–663. 2014.PubMed/NCBI
|
|
60
|
Denduluri SK, Idowu O, Wang Z, Liao Z, Yan
Z, Mohammed MK, Ye J, Wei Q, Wang J, Zhao L, et al: Insulin-like
growth factor (IGF) signaling in tumorigenesis and the development
of cancer drug resistance. Genes Dis. 2:13–25. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Sasaki H, Hikosaka Y, Okuda K, Kawano O,
Moriyama S, Yano M and Fujii Y: NFE2L2 gene mutation in male
Japanese squamous cell carcinoma of the lung. J Thorac Oncol.
5:786–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Takahashi T, Sonobe M, Menju T, Nakayama
E, Mino N, Iwakiri S, Nagai S, Sato K, Miyahara R, Okubo K, et al:
Mutations in Keap1 are a potential prognostic factor in resected
non-small cell lung cancer. J Surg Oncol. 101:500–506.
2010.PubMed/NCBI
|
|
63
|
Ishikawa T, Bao JJ, Yamane Y, Akimaru K,
Frindrich K, Wright CD and Kuo MT: Coordinated induction of
MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals
in human leukemia cells. J Biol Chem. 271:14981–14988. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Adachi T, Nakagawa H, Chung I, Hagiya Y,
Hoshijima K, Noguchi N, Kuo MT and Ishikawa T: Nrf2-dependent and
-independent induction of ABC transporters ABCC1, ABCC2, and ABCG2
in HepG2 cells under oxidative stress. J Exp Ther Oncol. 6:335–348.
2007.PubMed/NCBI
|
|
65
|
Singh A, Wu H, Zhang P, Happel C, Ma J and
Biswal S: Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer
cells that confers side population and chemoresistance phenotype.
Mol Cancer Ther. 9:2365–2376. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Saito H, Hirano H, Nakagawa H, Fukami T,
Oosumi K, Murakami K, Kimura H, Kouchi T, Konomi M, Tao E, et al: A
new strategy of high-speed screening and quantitative
structure-activity relationship analysis to evaluate human
ATP-binding cassette transporter ABCG2-drug interactions. J
Pharmacol Exp Ther. 317:1114–1124. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
zu Schwabedissen Meyer HE, Grube M,
Dreisbach A, Jedlitschky G, Meissner K, Linnemann K, Fusch C,
Ritter CA, Völker U and Kroemer HK: Epidermal growth
factor-mediated activation of the map kinase cascade results in
altered expression and function of ABCG2 (BCRP). Drug Metab Dispos.
34:524–533. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Hayes JD, McMahon M, Chowdhry S and
Dinkova-Kostova AT: Cancer chemoprevention mechanisms mediated
through the Keap1-Nrf2 pathway. Antioxid Redox Signal.
13:1713–1748. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhang P, Singh A, Yegnasubramanian S,
Esopi D, Kombairaju P, Bodas M, Wu H, Bova SG and Biswal S: Loss of
Kelch-like ECH-associated protein 1 function in prostate cancer
cells causes chemoresistance and radioresistance and promotes tumor
growth. Mol Cancer Ther. 9:336–346. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Singh A, Boldin-Adamsky S, Thimmulappa RK,
Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F,
Watson WH, et al: RNAi-mediated silencing of nuclear factor
erythroid-2-related factor 2 gene expression in non-small cell lung
cancer inhibits tumor growth and increases efficacy of
chemotherapy. Cancer Res. 68:7975–7984. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Tian Y, Liu Q, He X, Yuan X, Chen Y, Chu Q
and Wu K: Emerging roles of Nrf2 signal in non-small cell lung
cancer. J Hematol Oncol. 9:142016. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Qian Z, Zhou T, Gurguis CI, Xu X, Wen Q,
Lv J, Fang F, Hecker L, Cress AE, Natarajan V, et al: Nuclear
factor, erythroid 2-like 2-associated molecular signature predicts
lung cancer survival. Sci Rep. 5:168892015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Mahaffey CM, Zhang H, Rinna A, Holland W,
Mack PC and Forman HJ: Multidrug-resistant protein-3 gene
regulation by the transcription factor Nrf2 in human bronchial
epithelial and non-small-cell lung carcinoma. Free Radic Biol Med.
46:1650–1657. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Liu X, Sun C, Liu B, Jin X, Li P, Zheng X,
Zhao T, Li F and Li Q: Genistein mediates the selective
radiosensitizing effect in NSCLC A549 cells via inhibiting
methylation of the keap1 gene promoter region. Oncotarget.
7:27267–27279. 2016.PubMed/NCBI
|
|
75
|
Cho JM, Manandhar S, Lee HR, Park HM and
Kwak MK: Role of the Nrf2-antioxidant system in cytotoxicity
mediated by anticancer cisplatin: Implication to cancer cell
resistance. Cancer Lett. 260:96–108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Copple IM, Dinkova-Kostova AT, Kensler TW,
Liby KT and Wigley WC: NRF2 as an emerging therapeutic target. Oxid
Med Cell Longev. 2017:81654582017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Magesh S, Chen Y and Hu L: Small molecule
modulators of Keap1-Nrf2-ARE pathway as potential preventive and
therapeutic agents. Med Res Rev. 32:687–726. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Abed DA, Goldstein M, Albanyan H, Jin H
and Hu L: Discovery of direct inhibitors of Keap1-Nrf2
protein-protein interaction as potential therapeutic and preventive
agents. Acta Pharm Sin B. 5:285–299. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Harder B, Tian W, La Clair JJ, Tan AC, Ooi
A, Chapman E and Zhang DD: Brusatol overcomes chemoresistance
through inhibition of protein translation. Mol Carcinog.
56:1493–1500. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ren D, Villeneuve NF, Jiang T, Wu T, Lau
A, Toppin HA and Zhang DD: Brusatol enhances the efficacy of
chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Proc Natl Acad Sci USA. 108:1433–1438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Olayanju A, Copple IM, Bryan HK, Edge GT,
Sison RL, Wong MW, Lai ZQ, Lin ZX, Dunn K, Sanderson CM, et al:
Brusatol provokes a rapid and transient inhibition of Nrf2
signaling and sensitizes mammalian cells to chemical
toxicity-implications for therapeutic targeting of Nrf2. Free Radic
Biol Med. 78:202–212. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Kitamura H and Motohashi H: NRF2 addiction
in cancer cells. Cancer Sci. 109:900–911. 2018. View Article : Google Scholar : PubMed/NCBI
|
